Essential Science

Edzell, October 1 2007 - Essential Science Ltd is working with Biothera, Minnesota, USA to identify and develop licensing opportunities for Biothera’s novel, cotherapy, Imprime PGG.

Imprime PGG is a natural component of yeast cell walls. Biothera have extensive data including Phase I trial data supporting the mechanism of action and potential role of Imprime PGG as a cotherapy to enhance the biological and therapeutic activity of monoclonal antibody therapies in oncology. Biothera are initiating Phase II studies in combination with marketed antibody therapeutics and are interested in licensing and co-development partners for the technology.

Therapeutic efficacy continues to be a significant issue for many development stage monoclonal antibodies. Biothera’s Imprime PGG potentially represents a significant advance in enhancing MAb efficacy in a range of cancer indications.

For further information, contact:

Steve Smith, Director :: +33 545 31 55 90 :: steve@essentialscience.co.uk

About Essential Science

Essential Science Ltd supports technology clients in the development and exploitation of new technologies across the Life Science marketplace. As the number of available technologies grows and client success becomes increasingly dependent on the identification and exploitation of the right technologies, its experienced team, supported by an extensive associate network, is focused on establishing the partnerships that bring client technologies to market faster and more effectively.

Enquiries :: Neil Murray :: +44 1356 648941 :: neil@essentialscience.co.uk

Date :: Monday 16 July 2007